Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news the company has engaged the Centre for Human Drug Research and the pharmacy at the Leiden University Medical Center in the Netherlands conduct its Phase 1 DMT stroke study which is expected to begin in September of 2022. Moreau telling Proactive the study is being designed to investigate prolonged intravenous infusion of DMT, for durations which have never been clinically studied.
Algernon Pharmaceuticals Phase 1 DMT stroke study will start in September of 2022
